Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia.
- Author:
Ya Jun SHI
1
;
Ying HAN
1
;
Ying WANG
1
;
Dong Feng MAO
1
;
Jun Ling ZHANG
1
;
Rui XI
1
;
Hai BAI
1
;
Tao WU
1
Author Information
- Publication Type:Journal Article
- MeSH: Humans; Treatment Outcome; Antibodies, Bispecific/adverse effects*; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*; Antineoplastic Agents/adverse effects*; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- From: Chinese Journal of Hematology 2023;44(6):516-519
- CountryChina
- Language:Chinese
